TY - JOUR
T1 - Efficacy of brachytheraphy with californium-252 neutrons versus cesium-137 photons for eradication of bulky localized cervical cancer
T2 - Single-institution study
AU - Maruyama, Yosh
AU - Van Nagell, J. R.
AU - Yoneda, Justine
AU - Donaldson, Elvis
AU - Gallion, Holly
AU - Higgins, Robert
AU - Powell, Deborah
AU - Turner, Carol
AU - Kryscio, Richard
N1 - Funding Information:
1Received December 17, 1987; revised March 24, 1988; accepted March 25, 1988. 2Supported by research grant PDT-222B from the American Cancer Society. 3 The 252Cf was obtained by contract from the U.S. Department of Energy. 4Departments of Radiation Medicine (Y. Maruyama, J. Yoneda, C. Turner), Obstetrics and Gynecology (J. R. van Nagell, E Donaldson, H. Gal-lion, R. Higgins), Pathology (D. Powell), and Statistics {R Kryscio), Radiation Therapy Oncology Center, University of Kentucky Medical Center, Lexington, KY. 3 We thank Dr. D. Y. Hou, Ann Martin, Shartene West, and L. C. Wilson for their assistance in these studies and Angela Sandifer for expert clerical assistance. * Correspondence to: Yosh Maruyama, M.D., Department of Radiation Medicine, University of Kentucky Medical Center, 800 Rose St, Lexington, KY 40536.
Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.
PY - 1988/6/1
Y1 - 1988/6/1
N2 - A fast-neutron-emitting radioisotope, 252Cf, is being tested in clinical trials of neutron brachytherapy for cervical cancer. The efficacy for histological eradication of bulky stage IB cervical tumors (mean diameter, ∼6 cm) using combined radiation and surgery was studied in 65 patients treated with 137Cs or 252Cf before surgery during 1983-1986. Forty-four patients were treated with 137Cs and 21 were treated with 252Cf at equivalent doses of radiation. Fifteen of the 44 specimens (34%) were positive after 137Cs therapy. Only one of the 21 specimens was positive after 252Cf therapy (P = .025), and that patient was treated in a delayed schedule 21 days after the start of external-beam irradiation rather than early in the course. 252Cf therapy required a much lower radiation dose and shorter treatment time. The study compared tumor destruction of an identically staged human cervical tumor in situ by direct histological means, using 252Cf neutron therapy or conventional photon therapy at an identical and equivalent dose adjusted by a relative biological effectiveness of 6.0 for 252Cf.
AB - A fast-neutron-emitting radioisotope, 252Cf, is being tested in clinical trials of neutron brachytherapy for cervical cancer. The efficacy for histological eradication of bulky stage IB cervical tumors (mean diameter, ∼6 cm) using combined radiation and surgery was studied in 65 patients treated with 137Cs or 252Cf before surgery during 1983-1986. Forty-four patients were treated with 137Cs and 21 were treated with 252Cf at equivalent doses of radiation. Fifteen of the 44 specimens (34%) were positive after 137Cs therapy. Only one of the 21 specimens was positive after 252Cf therapy (P = .025), and that patient was treated in a delayed schedule 21 days after the start of external-beam irradiation rather than early in the course. 252Cf therapy required a much lower radiation dose and shorter treatment time. The study compared tumor destruction of an identically staged human cervical tumor in situ by direct histological means, using 252Cf neutron therapy or conventional photon therapy at an identical and equivalent dose adjusted by a relative biological effectiveness of 6.0 for 252Cf.
UR - http://www.scopus.com/inward/record.url?scp=0023915610&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023915610&partnerID=8YFLogxK
U2 - 10.1093/jnci/80.7.501
DO - 10.1093/jnci/80.7.501
M3 - Article
C2 - 3367388
AN - SCOPUS:0023915610
SN - 0027-8874
VL - 80
SP - 501
EP - 506
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 7
ER -
